Clinical Trials Browser

Not yet recruiting × OTHER × Nivolumab × Clear all

NCT06639607 2026-03-10

PRiME II

Phase 1/2 Not yet recruiting

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

NCT07460765 2026-03-10

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms, Squamous Cell

NCT07444619 2026-03-03

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

Phase 1 Not yet recruiting

Sarcoma

NCT07210632 2026-02-27

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

Phase EARLY_PHASE1 Not yet recruiting

Brain Neoplasms, Glioma

NCT07401875 2026-02-27

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

Phase 1 Not yet recruiting

Kidney Neoplasms

NCT07430202 2026-02-24

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Phase 1 Not yet recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT07420439 2026-02-19

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

Phase 2 Not yet recruiting

Lung Diseases, Interstitial

NCT07403877 2026-02-11

TORCH-OPTIMA

Phase 2 Not yet recruiting

Gastrointestinal

Turcot syndrome, Colorectal Neoplasms

NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Phase 1 Not yet recruiting

Neoplasm Metastasis

NCT07369791 2026-01-28

NOBLE

Phase 2 Not yet recruiting

Gastrointestinal

Advanced Biliary Tract Cancer(BTC)

NCT07355205 2026-01-21

FLINN

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07338981 2026-01-14

The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

Phase 3 Not yet recruiting

Advanced Kidney Cancer

NCT07233668 2025-12-03

IVE in mRCC

Phase NA Not yet recruiting

Carcinoma, Renal Cell

NCT07075120 2025-10-28

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

Phase 1 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07216833 2025-10-15

Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07187869 2025-09-23

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

Phase 1 Not yet recruiting

Carcinoma, Renal Cell

NCT06767956 2025-06-04

Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

Phase 1/2 Not yet recruiting

Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06692491 2024-11-18

SPRING

Phase 2 Not yet recruiting

Rare Tumour

NCT06572722 2024-08-27

Perioperative Immunotherapy for NSCLC (ECTOP-1030)

Phase 2 Not yet recruiting

Lung Neoplasms

NCT06554613 2024-08-15

Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06304597 2024-03-12

PREDICT

Phase 1 Not yet recruiting

Gastrointestinal

Locally Advanced Rectal Carcinoma

NCT05597800 2022-10-28

LUNGVIR

Phase 2 Not yet recruiting

Post-Acute COVID-19 Syndrome, Carcinoma, Non-Small-Cell Lung